Machupo Hemorrhagic Fever

Machupo hemorrhagic fever is a severe viral illness that affects the whole body. The virus is called Machupo virus, an arenavirus. People usually get infected after breathing in tiny particles from the urine, droppings, or saliva of infected wild rodents. Most known human cases have happened in northeastern Bolivia, especially in the Beni/Iténez region. The disease often starts like the flu with fever and body aches, then may progress to bleeding problems, low blood pressure, and, in serious cases, organ failure. Outbreaks have been documented since the late 1950s, with re-emergences in later years. Health-care related transmission has occurred, so strict infection control is essential. Fatality can be high without good supportive care. CDC+3PMC+3CDC+3

Machupo hemorrhagic fever is a severe viral illness that starts like the flu (fever, headache, body pain) and can progress to bleeding, low blood pressure, and organ problems. People become infected mainly by breathing in dust or touching food or items contaminated with the urine, droppings, or saliva of infected country mice (Calomys callosus). The virus can also spread from person to person in hospitals through blood or body fluids, so strict protection is needed. Death can happen from shock, bleeding, or organ failure. There is no licensed vaccine for public use. Good rodent control, safe food storage, and careful hospital practices can prevent illness. PMC+3CDC+3Iris+3

The main risk is contact with the natural animal host, a wild rodent known as the large vesper mouse (Calomys callosus). These rodents can carry the virus for a long time and shed it in their excreta while appearing healthy, which helps the virus persist in nature. People can get infected by inhaling contaminated dust, handling contaminated grain or food, or touching contaminated surfaces and then the eyes, nose, or mouth. Rare person-to-person spread has been reported in hospitals. CDC+2PubMed+2

Arenaviruses that cause South American hemorrhagic fevers (like Machupo) are considered high-risk pathogens needing biosafety level-4 conditions for laboratory work and rapid public-health action during suspected outbreaks. IJID Online

---

Other names

• Bolivian hemorrhagic fever (BHF). This is the standard public-health name used in official reports. CDC

• Black typhus / “Ordog fever.” These older or lay terms sometimes appear in historical or secondary sources; the medical literature primarily uses “Bolivian hemorrhagic fever” due to Machupo virus. (Use with caution; prefer BHF in clinical writing.) Wikipedia

---

Types

Strict “subtypes” are not used the way they are for some diseases. Clinicians usually group cases by stage, setting, or severity:

1. By clinical stage

• Prodromal (early) phase. Fever, headache, muscle and joint pain, sore throat, and tiredness. People often think it is the flu at first. OUP Academic+1

• Hemorrhagic (critical) phase. Bleeding from gums or nose, easy bruising, tiny skin bleeds (petechiae), eye redness or bleeding, low blood pressure, and sometimes confusion, tremor, seizures, or coma. OUP Academic

• Convalescent (recovery) phase. Fever settles, strength slowly returns, but people may feel weak for weeks. Some have lingering nerve symptoms such as tremor. PubMed

2. By setting of infection

• Community-acquired. Infection linked to rodent exposure during farm work, grain storage, sweeping, or home activities in endemic areas. Iris

• Health-care–associated (nosocomial). Infection in a clinic or hospital due to close contact without proper protection. Rare, but documented. Wikipedia

3. By severity

• Uncomplicated. Flu-like illness that improves with supportive care.

• Severe/complicated. Bleeding, shock, or neurologic problems requiring intensive care. (This pattern is reported across viral hemorrhagic fevers.) NCBI

---

Causes

Here “cause” means things that allow the virus to reach a person or raise the chance of severe disease.

1. Breathing dust contaminated with rodent urine or droppings. Cleaning barns, granaries, or homes with infestations can aerosolize particles. Iris

2. Handling food or grain contaminated by infected rodents. Rodents shed virus onto stored grains; handling or eating contaminated food is risky. CDC

3. Touching contaminated surfaces then touching eyes/nose/mouth. The virus can enter through mucous membranes. Iris

4. Living or working in endemic rural areas of Bolivia (e.g., Beni/Iténez). Geography matters because the reservoir lives there. ScienceDirect

5. High household rodent density. More rodents means more shedding and higher exposure chances. CDC

6. Poor rodent-proofing of homes and storage buildings. Open grain storage and gaps let rodents in. Iris

7. Sweeping or dry cleaning of rodent-contaminated areas. Dry sweeping stirs up dust; wet cleaning is safer. Iris

8. Farming and harvesting activities. Field work and grain handling increase exposure. Iris

9. Sleeping on floors where rodents roam at night. Closer contact with contaminated dust and droppings. Iris

10. Nosocomial exposure without PPE. Close, unprotected care of a sick patient can transmit infection. Wikipedia

11. Laboratory exposure. Work with arenaviruses requires BSL-4; accidents can be dangerous. IJID Online

12. Transport or storage of rodent-contaminated goods. Moving contaminated sacks can release aerosols. Iris

13. Children playing in infested storage areas. Hand-to-mouth behavior raises risk. Iris

14. Lack of community rodent control. Without coordinated efforts, reservoirs persist near homes. Iris

15. Open refuse or animal feed near dwellings. Food sources attract rodents. Iris

16. Cracks and holes in walls or floors. Entry points allow rodents to nest indoors. Iris

17. Displaced rodents after floods or land changes. Environmental disruption can drive rodents into homes. (Inference consistent with rodent-borne VHF ecology.) PMC

18. Handling wild rodents. Trapping or contact during hunting or pest control raises risk. Iris

19. Consumption of food not washed or covered in rodent-exposed settings. Reduces but does not eliminate risk to keep foods covered. CDC

20. Lack of awareness during known outbreaks. Without precautions, exposure continues; past clusters show family-household spread linked to shared environments. CDC+1

---

Symptoms

1. Fever. The body temperature rises suddenly as the immune system reacts to the virus. OUP Academic

2. Headache. Inflammation during infection makes the head ache or feel heavy. OUP Academic

3. Muscle and joint pain. The whole body can ache like the flu. OUP Academic

4. Weakness and tiredness. People feel drained because the body is fighting a strong infection. OUP Academic

5. Sore throat. Early irritation of the throat is common in the prodrome. OUP Academic

6. Nausea or vomiting. The stomach is upset, and eating is hard. OUP Academic

7. Bleeding from gums or nose. The virus and the body’s response affect blood vessels and clotting, causing bleeding. OUP Academic

8. Easy bruising and petechiae (tiny red dots). Small skin bleeds happen when platelets and vessels are affected. OUP Academic

9. Red eyes or eye bleeding. Fragile eye vessels can leak blood. OUP Academic

10. Stomach or gut bleeding (vomiting blood or black stools). Severe cases may bleed internally. OUP Academic

11. Low blood pressure and dizziness. Fluid loss and vessel leak lead to shock if untreated. NCBI

12. Tremor. Shaking can occur as the nervous system is affected. OUP Academic

13. Seizures. In very severe illness, the brain can be involved. OUP Academic

14. Confusion or coma. Low blood pressure, bleeding, or direct effects on the brain can impair consciousness. OUP Academic

15. Slow recovery and long fatigue. Even after fever stops, energy can stay low for weeks. PubMed

---

Diagnostic tests

Doctors combine clinical assessment with laboratory tests. Confirmatory tests require specialized labs. Because this is a high-risk pathogen, suspected samples must be handled under strict safety rules.

A) Physical examination (bedside observations)

1. Temperature measurement. Confirms fever pattern and helps track response to care. NCBI

2. Blood pressure and pulse checks (including shock signs). Detects low pressure, fast pulse, and poor perfusion—early warnings of severe disease. NCBI

3. Skin and mucous membrane inspection. Looks for petechiae, bruises, and gum bleeding that signal a hemorrhagic process. OUP Academic

4. Eye exam. Finds conjunctival injection or subconjunctival hemorrhage (red eyes or bleeding). OUP Academic

5. Neurologic check. Assesses tremor, seizures, and level of consciousness to judge severity and need for monitoring. OUP Academic

B) “Manual” clinical tests (simple bedside maneuvers and point-of-care checks)

6. Orthostatic vital signs. Standing blood pressure and pulse help reveal volume loss or early shock. NCBI

7. Capillary refill time. A quick finger-press test to see if blood flow to skin is slow, a clue to poor circulation. NCBI

8. Bedside urine dipstick. Checks for blood or protein in urine, which can occur with systemic illness. (Formal lab urinalysis follows if positive.) NCBI

9. Point-of-care glucose. Severe infection can disturb glucose; low or high values guide urgent care. NCBI

10. Bedside coagulation assessment (bleeding observation after venipuncture). Persistent oozing suggests a clotting problem and prompts full lab coagulation tests. NCBI

C) Laboratory and pathological tests (key to diagnosis)

11. Complete blood count (CBC). Often shows low platelets and low white cells; these findings support a hemorrhagic fever picture. NCBI

12. Liver function tests (ALT/AST, bilirubin). Elevations suggest liver involvement common in VHFs. NCBI

13. Renal function (creatinine, BUN, electrolytes). Assesses kidney stress or failure during severe disease. NCBI

14. Coagulation panel (PT/INR, aPTT, fibrinogen, D-dimer). Detects clotting disorders that lead to bleeding. NCBI

15. RT-PCR for Machupo virus. Detects viral RNA in blood or other appropriate samples and provides confirmatory diagnosis in specialized labs. (Handled under high biosafety precautions.) PubMed

16. Antigen-capture ELISA. Looks for viral proteins during acute illness when viral load is high (specialized reference labs). PubMed

17. IgM/IgG serology. IgM suggests recent infection; IgG appears later or after recovery; paired samples can confirm infection. PubMed

18. Virus isolation in culture (BSL-4 only). Not routine clinically due to risk; used in research or reference settings. IJID Online

19. Blood cultures for bacteria (to rule out other causes). Helps exclude sepsis or typhoid that can mimic early symptoms. NCBI

20. Additional rule-out tests (malaria smear/rapid test, dengue tests, etc.). In the right geography, doctors test for other endemic illnesses that look similar, to avoid missing a treatable disease. NCBI

D) Electrodiagnostic tests (when indicated)

• Electrocardiogram (ECG). Monitors heart rate and rhythm during shock or electrolyte problems; helps guide fluids and critical care. NCBI

• Electroencephalogram (EEG). Considered if seizures or unexplained confusion occur to assess brain involvement and guide anti-seizure therapy. OUP Academic

E) Imaging tests (used selectively)

• Chest X-ray. Looks for pneumonia, fluid in lungs, or bleeding-related changes in severe disease. Helps with supportive care decisions. NCBI

• Abdominal ultrasound. Checks liver and spleen size and free fluid; noninvasive and useful at bedside. NCBI

• CT or MRI brain (if neurologic signs). Used for severe headache, seizures, or coma to rule out bleeding or other brain problems. OUP Academic

• Point-of-care ultrasound (POCUS) for shock. Helps assess fluid status and heart function quickly in unstable patients. NCBI

Non-pharmacological treatments (therapies & other measures)

1. Strict isolation & infection-control precautions — Place the patient in a single room, limit visitors, and use gloves, gowns, eye protection, and respirators during procedures with splash/aerosol risk. Purpose: protect healthcare workers and others. Mechanism: physical barriers and safe handling of blood/fluids block contact and droplet exposure. CDC

2. Supportive fluid therapy (oral/IV) — Give oral rehydration or IV fluids to correct dehydration and maintain blood pressure. Purpose: stabilize circulation and organs. Mechanism: replaces fluid losses from fever, vomiting, and capillary leak to keep tissues perfused. PMC

3. Careful blood-pressure support — If fluids are not enough, clinicians may use vasopressors (drug therapy) alongside non-drug measures like leg elevation and frequent vital-sign checks. Purpose: prevent shock. Mechanism: restores adequate organ blood flow with the least invasive steps first. PMC

4. Oxygen therapy — Nasal oxygen or masks as needed. Purpose: correct low oxygen and reduce strain on the heart and brain. Mechanism: increases oxygen delivery while the body fights the virus. PMC

5. Temperature control — Cooling blankets, tepid sponging, light clothing, and room ventilation. Purpose: manage high fever safely. Mechanism: physical cooling helps comfort and reduces fluid loss from sweating. PMC

6. Bleeding precautions — Minimize needle sticks, use soft toothbrushes, avoid intramuscular injections, and handle blood draws gently. Purpose: lower the risk of bleeding. Mechanism: reduces trauma in a patient with fragile clotting. PMC

7. Nutritional support — Small, easy-to-digest meals; if too ill to eat, clinicians consider tube feeding. Purpose: maintain strength and healing. Mechanism: steady calories and protein support immune function and recovery. PMC

8. Pain and nausea relief (non-drug strategies) — Rest, quiet room, guided breathing, hydration, ginger tea or bland foods. Purpose: reduce distress and vomiting. Mechanism: calming environment and gentle diet decrease triggers for nausea and strain. PMC

9. Skin and mouth care — Soft swabs, saline rinses, and moisturizers. Purpose: reduce bleeding and secondary infections. Mechanism: gentle hygiene protects fragile tissues. PMC

10. Fall and seizure precautions — Padded bedrails, assisted walking, close observation. Purpose: prevent injury if weakness or confusion occurs. Mechanism: environmental safety measures reduce trauma risk. PMC

11. Respiratory hygiene — Tissues, covered coughs, mask for patient during transport. Purpose: reduce exposure to droplets. Mechanism: blocks spread of contaminated secretions. CDC

12. Safe handling and disposal of waste/linens — Dedicated containers, careful laundering/incineration per VHF guidance. Purpose: environmental safety. Mechanism: contains potentially infectious materials. CDC

13. Point-of-care clustering — Bundle tasks to minimize room entries. Purpose: reduce exposure opportunities. Mechanism: fewer contacts mean fewer chances for transmission. CDC

14. Psychological support — Clear communication, family updates, and calm routines. Purpose: reduce fear and stress. Mechanism: reassurance and orientation support coping during isolation. PMC

15. Careful monitoring — Frequent checks of vitals, urine output, mental state. Purpose: catch deterioration early. Mechanism: timely detection guides prompt interventions. PMC

16. Laboratory monitoring (minimal-exposure setup) — Use closed systems and strict biosafety for essential labs only. Purpose: guide therapy safely. Mechanism: balances clinical needs with staff protection. CDC

17. Transfusion support (non-drug measure) — Platelets, plasma, or red cells as clinically indicated (ordered by physicians). Purpose: manage bleeding or severe anemia. Mechanism: replaces what is lost and supports clotting. PMC

18. Public health notification & contact tracing — Alert health authorities; trace contacts. Purpose: stop outbreaks. Mechanism: early isolation of contacts and education reduce spread. CDC

19. Rodent control in affected communities — Trapping, sealing homes, safe food storage, cleaning droppings safely. Purpose: prevent new infections. Mechanism: removes or blocks the rodent reservoir. CDC+2Iris+2

20. Community education — Avoid sweeping dusty rodent areas, wet-mop instead; protect food; seek care early. Purpose: reduce exposure. Mechanism: simple behavior changes cut risk from contaminated dust and food. CDC

---

Drug treatments

Important disclaimer: No medicine is FDA-approved specifically for Machupo hemorrhagic fever. Some medicines below are investigational for BHF (e.g., ribavirin) or are FDA-approved for other conditions and used only to treat complications (fever, nausea, ulcers, superinfections, etc.). Drug choices and doses must be set by clinicians based on each patient’s condition, risks, and evolving evidence. PMC

Antiviral/virus-targeted (investigational or limited evidence for BHF):

1. Ribavirin (investigational for BHF) — Broad-spectrum antiviral with anecdotal human use in BHF and more data in Lassa fever. Class: nucleoside analog. Purpose/Mechanism: inhibits viral RNA synthesis; potential benefit if given early. Side effects: hemolytic anemia is the key risk in labeled use. Note: FDA labeling covers hepatitis C combos, not BHF. Dosing for BHF is not established; any use is compassionate/investigational. FDA Access Data+4PubMed+4OUP Academic+4

2. Favipiravir (investigational) — RNA polymerase inhibitor studied for various RNA viruses. Purpose: theoretical activity against arenaviruses; human data in BHF are insufficient. Mechanism: introduces lethal mutagenesis in RNA viruses. Side effects: teratogenic concerns; GI upset. Regulatory: not FDA-approved for BHF. (Evidence base for arenaviruses is preclinical/limited.) PMC

3. Monoclonal antibodies/immune plasma (experimental) — Effective immune plasma is proven for Junín (Argentine hemorrhagic fever), but for Machupo, evidence is limited. Purpose/Mechanism: passive antibodies neutralize virus. Risks: transfusion reactions; availability issues. PMC

Medications to treat complications (FDA-approved for their own indications; not disease-specific to BHF):

The following examples are standard in critical-care/supportive management; exact drug, dose, route, and timing must be individualized by treating clinicians.

4. Acetaminophen — For fever and pain (avoid NSAIDs if bleeding risk). Mechanism: central antipyretic effect. Risks: liver toxicity in overdose. (Labeling: analgesic/antipyretic; not specific to BHF.)

5. Ondansetron — For severe nausea/vomiting. Mechanism: 5-HT3 receptor blockade. Risks: QT prolongation. (Labeling: antiemetic.)

6. Proton-pump inhibitor (e.g., pantoprazole) — For stress-ulcer prophylaxis in critically ill. Mechanism: suppresses gastric acid to lower GI bleeding risk. Risks: C. difficile risk, low Mg with prolonged use.

7. Tranexamic acid (case-by-case) — Antifibrinolytic sometimes considered for mucosal bleeding; risk-benefit must be assessed due to thrombosis risk.

8. Electrolyte replacements (K+, Mg2+, PO4) — Corrects deficits from vomiting/diarrhea. Mechanism: restores cellular function; prevents arrhythmias.

9. Crystalloids (IV normal saline/Ringer’s) — To treat dehydration and early shock. Mechanism: volume expansion.

10. Vasopressors (e.g., norepinephrine; clinician-directed) — For septic-like shock unresponsive to fluids. Mechanism: alpha-adrenergic vasoconstriction to maintain perfusion.

11. Broad-spectrum antibiotics (when bacterial coinfection is suspected) — Not for the virus, but for possible secondary infection. Mechanism: bacterial killing to reduce sepsis risk.

12. Anticonvulsants (e.g., levetiracetam; if seizures) — Stabilize neuronal firing. Mechanism: modulates synaptic release.

13. Insulin (if stress hyperglycemia) — Controls glucose to aid healing. Mechanism: improves cellular uptake of glucose.

14. Thiamine & multivitamins — Support metabolism in critical illness. Mechanism: cofactor replacement.

15. Topical oral hemostatics (e.g., tranexamic mouthwash under supervision) — Local bleeding reduction.

16. Sedation/analgesia protocols (ICU) — Reduce agitation and metabolic demand. Mechanism: dampens sympathetic surge.

17. Nebulized bronchodilators (if bronchospasm) — Open airways. Mechanism: beta-2 agonism.

18. Antidiarrheals (judicious, if no red flags) — Reduce fluid loss.

19. Antipyretic sponging plus medications (combined) — Temperature control strategy.

20. Vaccinations for contacts (not BHF-specific; per local guidance) — e.g., tetanus if injuries; general health optimization during outbreaks.

(Where possible, supportive-care roles are summarized from peer-reviewed reviews and CDC VHF guidance; drug labels for ribavirin are from FDA documents that do not indicate BHF.) FDA Access Data+3PMC+3CDC+3

---

Dietary molecular supplements

No supplement cures BHF. These are general critical-illness adjuncts sometimes considered to support nutrition/antioxidant status; use must be individualized and approved by clinicians, especially due to bleeding risk.

1. Oral rehydration salts (ORS) — Balanced glucose-electrolyte solution to correct dehydration and support circulation. Typical dosing follows WHO packets as directed. Function/Mechanism: glucose-sodium co-transport enhances water absorption; helps maintain perfusion while awaiting IV access. PMC

2. Zinc — Supports mucosal integrity and immunity. Common doses 10–20 mg elemental/day in deficiency; avoid excess. Mechanism: cofactor for enzymes in innate/adaptive responses; may aid gut barrier.

3. Vitamin C — Antioxidant supporting collagen and capillaries. Doses vary (e.g., 200–500 mg/day orally in diet support). Mechanism: scavenges reactive oxygen species; supports wound healing.

4. Vitamin D — Immune modulation; correct deficiency per guidelines. Mechanism: regulates innate/adaptive responses and barrier function.

5. Vitamin A (retinol) — Epithelial health; avoid in pregnancy/high doses. Mechanism: maintains mucosal barriers and immune signaling.

6. B-complex (esp. thiamine) — Energy metabolism; helps when intake is poor. Mechanism: coenzymes in carbohydrate metabolism and neural function.

7. Selenium — Antioxidant enzyme cofactor (glutathione peroxidase). Mechanism: counters oxidative stress in critical illness; dosing must avoid toxicity.

8. Glutamine (nutrition-team directed) — Enteral amino acid to support gut barrier; mixed evidence. Mechanism: fuel for enterocytes and immune cells.

9. Omega-3 fatty acids — Anti-inflammatory nutrition support; fish-oil-based formulas under supervision. Mechanism: resolvin pathways modulate inflammation; watch bleeding risk.

10. Probiotics (case-by-case) — Gut-microbiome support in recovery; avoid in severe immunosuppression. Mechanism: colonization resistance; SCFA production.

(General nutrition concepts; not disease-specific curatives.) PMC

---

Immunity-booster / regenerative / stem-cell” drugs

There are no approved immune-booster or stem-cell drugs for Machupo hemorrhagic fever. Below are concepts used in other contexts that are not curative for BHF and should not be self-administered. Any consideration is research-only or for complications under specialist care:

1. Convalescent plasma / hyperimmune products (experimental) — Passive antibodies; limited/uncertain for Machupo. Mechanism: neutralize virus; risk of reactions. PMC

2. Monoclonal antibodies (research) — Virus-specific mAbs under development for arenaviruses; none approved for BHF. Mechanism: targeted neutralization. PMC

3. IV immunoglobulin (IVIG) — Non-specific antibodies sometimes used for immune modulation; no proven benefit in BHF. Mechanism: Fc-mediated immune balancing. PMC

4. Interferon-based therapies (research context) — Broad antiviral signaling; adverse-effect profile significant; not BHF-proven. Mechanism: induces antiviral state. PMC

5. Hematopoietic growth factors (e.g., G-CSF) for severe neutropenia — Only if clinically indicated for marrow suppression; not antiviral. Mechanism: stimulates neutrophil production. PMC

6. Cell therapies (experimental) — No approved stem-cell therapy for BHF; any use should be within rigorously approved trials. Mechanism: theoretical tissue support. PMC

---

Surgeries

There are no surgeries that treat Machupo virus itself. Procedures are limited to supporting complications (all are physician-directed):

1. Central venous catheter placement for difficult IV access and vasoactive infusions (why: secure access in shock).
2. Airway procedures (intubation) if respiratory failure (why: protect airway/ventilate).
3. Bleeding control procedures (e.g., endoscopic hemostasis) if severe GI bleeding (why: stop life-threatening hemorrhage).
4. Chest procedures for large effusions threatening breathing (why: relieve compression).
5. Dialysis catheter placement if acute kidney failure requires renal support (why: enable dialysis). PMC

---

Proven prevention

1. Keep rodents out: seal holes, use traps, and store food in rodent-proof containers. CDC

2. Clean rodent areas safely: wet-mop (don’t sweep), wear gloves, and disinfect. CDC

3. Protect food and water: keep lids tight; avoid food possibly contaminated by rodents. CDC

4. Home hygiene: remove clutter where mice nest. CDC

5. Community rodent control: coordinate trapping and environmental measures. Iris+1

6. Early care-seeking for fever/bleeding if you live in or visited risk areas. PMC

7. Hospital infection control: isolation, PPE, and safe waste handling. CDC

8. Avoid aerosolizing dust in barns/grain storage; ventilate first. CDC

9. Educate family/workers about rodent risks and safe cleanup. CDC

10. Public health partnership: report suspected cases promptly. CDC

---

When to see a doctor (urgent)

Seek urgent medical care immediately if you live in or recently visited parts of Bolivia where BHF is known and you develop fever, bleeding from gums or nose, severe headache, confusion, shortness of breath, vomiting/diarrhea, or fainting/very low blood pressure. Early hospital care improves survival, and hospitals can protect others with strict infection control. PMC+1

---

What to eat / what to avoid

Eat: small, frequent, soft foods (rice, bananas, bread, yogurt, soups), ORS, and protein sources as tolerated (eggs, lentils, fish). These are gentle on the stomach and help maintain strength and fluids. Avoid: alcohol, raw or unwashed foods, very spicy/oily meals, and over-the-counter NSAIDs (like ibuprofen) without clinician approval because of bleeding risk. Always follow hospital nutrition advice if admitted. PMC

---

Frequently asked questions

1) Is there a cure for Machupo hemorrhagic fever?
No. There is no FDA-approved antiviral or vaccine for BHF. Care is supportive. PMC

2) Has ribavirin helped?
There are case reports where IV ribavirin was given and patients recovered, but controlled data for BHF are lacking; benefit is uncertain. PubMed+1

3) Is ribavirin FDA-approved for BHF?
No. U.S. labeling covers hepatitis C combinations, not Machupo; it also carries notable risks (e.g., hemolytic anemia). FDA Access Data+1

4) How contagious is BHF between people?
Person-to-person spread appears limited but standard VHF precautions are essential in hospitals. CDC

5) How do people get infected?
Mostly from exposure to rodent urine/droppings or contaminated dust/food. CDC

6) What’s the fatality rate?
Reported fatality has varied by outbreak; BHF can be severe without expert care. (Ranges differ by report and era.) PMC

7) Can antibiotics cure it?
No. Antibiotics treat bacteria, not viruses; they’re used only for suspected bacterial coinfections. PMC

8) What about immune plasma or monoclonal antibodies?
Immune plasma is proven for Junín fever; for Machupo, evidence is limited and experimental. PMC

9) What should families do at home?
Rodent-proof the home, store food safely, clean droppings carefully (wet-mop, disinfect), and seek care early for fever/bleeding. CDC

10) Are there long-term effects after recovery?
Some survivors of arenavirus hemorrhagic fevers report prolonged weakness; careful follow-up is advised. PMC

11) Could BHF be used as a biothreat?
Arenaviruses are discussed in biodefense literature; this is why strict hospital precautions exist. PMC

12) Is there a vaccine under development?
Research continues, but no licensed vaccine exists yet for Machupo. PMC

13) Should I take NSAIDs for fever?
Only if a clinician says it’s safe; bleeding risk is a concern. Acetaminophen is often preferred. PMC

14) What tests confirm BHF?
Specialized labs perform PCR or serology; samples require high biosafety handling. PMC

15) What community actions help most?
Sustained rodent control programs and public education have dramatically reduced outbreaks in affected regions. CDC+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 29, 2025.